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Introduction
Efforts to improve response of  breast tumours to 
chemotherapy and maximize the benefit-to-adverse events 
ratio of  chemotherapy include molecular subtyping to 
classify tumours, combined and cyclical use of  chemotherapy 
and surgical de-bulking to stimulate proliferation. 
Molecular characteristics influence response to neoadjuvant 
chemotherapy (NAC). Whether physical characteristics 
such as size will have similar influence and impact type of  
chemotherapy regimen for breast cancer is inconclusive. 
Drawing from understanding of  tumour kinesis, NAC is 
expected to be less active on larger tumours due to lower 
growth index; hence we expect size of  breast tumour to 
influence response to NAC. Surprisingly, clinical evidence is 
equivocal on this and other related issues such as correlation 
of  breast tumour size to survival and correlation of  breast 
tumour size to rate of  pathologic complete response1-3. An 
early report by Fisher et al suggested that tumour size was an 
independent predictor of  complete response to neoadjuvant 
chemotherapy4. Contrary to intuition, a report by Baron et al 
on data from 62 institutions in the United States of  America 
did not find significant relationship between tumour size and 
pathologic complete response to neoadjuvant chemotherapy1. 
In contrast, a report by Goorts et al with data from  the 
nationwide cancer register in Netherlands found that tumour 
size was an independent predictor of  pathologic complete 
response2.
Data on NAC is scarce from developing countries where 
this tool is needed the most because breast cancer patients 
present late with locally advanced disease5-9. In Nigeria, the 
few available reports show contrasting findings. In 2010, 
Arowolo et al5 in southwestern Nigeria and Anyanwu et6 al 
in eastern Nigeria reported that breast tumour size affected 
response to chemotherapy. In 2013, a retrospective study 
from eastern Nigeria by Egwuongu et al upheld a contrary 
view7. Egwuongu et al7 stated that size was not a determinant 
of  response to NAC. 
In developing countries, primary breast cancer tumours in 
excess of  5cm diameter is the norm. Clinicians in Nigeria 
and many developing countries frequently face the challenge 
of  making treatment decisions on large tumours sometimes 
ranging beyond 30cm in diameter and sometimes occupying 
the whole breast6,8-10. Despite this, relationship between size 
and physical characteristics of  tumour and response to NAC 
has not be adequately studied in these centres and the role of  
size as a physical factor predicting response to chemotherapy 
has not been clarified.
Among breast cancer patients presenting with large tumours, 
sorting probable responders from probable non-responders 
will help tailor treatment and eliminate inadvertent delays 
in instituting the most beneficial regimen. Therefore, we 
reviewed the records of  breast cancer patients treated in a 
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tertiary institution in Nigeria where breast cancer patients 
presented with large tumour volumes. In this report, we 
described the relationship between tumour size and response 
to NAC with the aim of  providing information which may 
impact chemotherapy selection and guide further research. 
Method
This was a retrospective study conducted at the General 
Surgery Division of  the Department of  Surgery of  
University of  Ilorin teaching Hospital Ilorin, North-central 
Nigeria. After obtaining ethical clearance, we reviewed the 
records of  women who presented with locally advanced 
breast cancer and received NAC between January of  2013 
and June of  2015. Only records of  patients whose diagnosis 
was confirmed by cytology or histology were included. 
Records of  inflamed, ulcerated and fungating lesions were 
included because these tumours constituted major treatment 
challenges in our clinical practice. Records of  patients with 
recurrent lesions were excluded. Data was separated into 2 
groups based on size of  the primary tumour. Records where 
tumour size was less than 100mm were placed in group 1 and 
records where tumour size was at least 100mm were placed 
in group 2.
We hypothesized that there was at least 50% difference 
in proportion of  patients who achieved 50% reduction in 
tumour size when tumour ≥100mm were compared with 
those ≥100mm in widest diameter. Cut-off  of  100mm size 
was used for group separation in this study because previous 
studies in Nigeria showed conflicting reports based on cut-
off  value of  100 mm7,11. 50% cut-off  was elected because 
tumours previously reported in the study centre and Nigeria 
were large5, 7, 10; thus, small changes in tumour size was often 
not sufficient to advance patient care. Data extracted from 
eligible records included information about maximum of  6 
cycles of  NAC. Information beyond the 6th cycle of  NAC 
was excluded. Other information extracted were the age and 
sex of  the patients, and the physical characteristics of  the 
primary tumours. 
The comparison between the groups was by chi-square test 
of  independence. The primary tumour characteristics, the 
types and duration of  NAC were presented in descriptive 
statistics. The significance level was placed at 0.05. Reduction 
in tumour size based on Response Evaluation Criteria In 
Solid Tumours (RECIST) was secondary analysis. At the time 
of  this study, treatment of  breast cancer was not biologically 
directed at our centre. Immunohistochemistry was reserved 
for mastectomy specimen due to cost. 
Results 
A total of  57 case notes were eligible for analysis (group 1= 24, 
group 2= 33). All were from female patients and  65% were 
premenopausal. Mean age was 47.9 ± 13.1(range 28-85). The 
range of  NAC was 2-6 cycles (median 4). Widest diameter of  
tumours ranged from 30mm to 180mm (median 100mm). 
The groups’ demographics were as presented in table 1. 
The NAC regimens used were FEC (5-Fluorouracil 600mg/
m2, Epirubicin 60mg/m2, Cyclophosphamide 600mg/
m2, or TX ( Docetaxel 75mg/m2, Capecitabine 1000mg/
m2 twice daily for 14 days) or TEC (Docetaxel 75mg/m2, 
Epirubicin 60mg/m2, Cyclophosphamide 600mg/m2). Each 
regimen was repeated 3-weekly. Among the 57 case notes 
reviewed, 17 received taxane based agents while 40 received 
anthracycline based regimen. In group 1, 17 patients received 
anthracycline based NAC while in group 2, 23 patients 
received anthracycline based NAC. 50% reduction in tumour 
size was achieved in 45.8% and 6.0% among the groups 
1 and 2 respectively (p= 0.0001).  50% reduction rate for 
those who received taxane and anthracycline based agents 
was 54.5% and 21.2% respectively. The overall response by 
RECIST assessment was as shown in figure 1. Goodness-of-
fit analysis for the distribution of  RECIST response between 
the two groups returned p value 0.004 (table 2). 
Table 1: Locoregional physical characteristics of breast tumors
GROUP1 <100mm) n= 24 GROUP 2 ≥ 100mm) n= 33
Age (mean ± SD) 48.5 ± 12.8 47.4 ±13.4
PRIMARY BREAST TUMOR
min Area(mm) 12 160 
Max Area(mm) 84 2250
Mean Area(mm2) 48.9±35.4 37 ±68.1
Min Diameter(mm) 3 10
max Diameter(mm) 8 18
Mean Diameter(mm) 7.2 ± 1.6 12.2 ± 2.9
INDICATION FOR NAC
Large tumor breast 
ratio
8 8
Large tumor and fixity 3 2
Large tumor and 
matted/fixed nodes
4 6
Large and ulcerated 
tumor
2 5
Large ulcerated tumor 
and fixed/matted node
3 4
Large fixed tumor and 
fixed/matted nodes
3 1
Large fixed and 
ulcerated tumor and 
matted/fixed node
1 3
Fungating tumor 0 4
Figure 1: Overall rate of response according to 
RECIST criteria
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Table 2: Frequency of response according to RECIST criteria





Partial Response 10 7
Complete Response 4 0
..p=0.004
Discussion
Cytotoxic destroy cancerous cells but they are nonspecific 
in their mechanism of  action; hence, while they can be 
beneficial in treatment of  cancer, they can also cause 
dangerous adverse events such as bone marrow suppression, 
cardiotoxicity, infertility and even secondary carcinogenesis. 
The dangerous adverse effects of  chemotherapy propel the 
continuous efforts to maximize the benefit to risk ratio of  
these drugs12.
Most carcinomas of  the breast cancer patients in developing 
countries require neoadjuvant chemotherapy because they 
present with bulky tumors and large burden of  disease. 
Yet, there has been underreporting of  the primary tumor 
characteristics and response to NAC in these centers. 
Researchers in South-western Nigeria terminated a phase II 
clinical trial on capecitabine neoadjuvant chemotherapy with 
under accrual due to prevalence of  fungating, edematous 
and large tumors which were among their exclusion criteria11.
In this study, we reviewed the response to chemotherapy of  
57 patients who had received NAC and we compared the 
response of  tumors more than ≥100mm (Group 1) with 
the response in those ≥100 mm (Group2). The patients’ 
demographics were similar to previous documentation in 
Nigeria. Reports of  NAC in developed countries suggest 
response rate ranging from 50-80% with a high rate of  
complete response. Previous reports by Arowolo et al5 and 
Egwuonwu et al7 in Nigeria were 51% and 74% response rate 
respectively. This is the first report focusing on the effect of  
NAC on primary breast tumor in our center and our review 
revealed that more than 80% of  patients benefitted from 
NAC and 37.8% were either partial or complete response 
(figure 1). However, the rate of  complete and partial response 
was lower than previously documented in Nigeria5, 7.
According to RECIST assessment, the numbers of  partial 
and complete response were significantly higher among 
group 1 ( ≥100 mm) (p = 0.004). In contrast to the findings 
by Egwuonwu et al7 and in agreement with Arowolo et 
al5,our result showed that response to chemotherapy was 
related to tumor size.
Most of  the studies on NAC in Nigeria employed anthracycline 
based chemotherapy. Cases in this review received either 
anthracycline based or taxane based polychemotherapy. 
Among the 57 records reviewed, 17 received taxane based 
regimen while 40 received anthracycline based regimen. 
Exploratory analysis among 33 records where patients 
had tumors ≥100mm showed that taxanes elicited higher 
response rates than the anthracycline based chemotherapy 
(figure 2). However, this finding should be interpreted in 
the light of  limitations of  a retrospective design, treatment 
was not directed by molecular biology and treatment groups 
were unmatched.
Understanding of  the tumor kinesis and mechanism of  
action of  antineoplastic agents is essential in determining 
expectations from treatment. This will prevent needless 
exposure to impotent treatments and increase the benefit-
to-risk ratio of  NAC. This report supports our expectation 
based on basic understanding that there is a relationship 
between breast cancer tumour size and response to NAC. 
This suggests that treatment regimen for management 
of  tumors may vary depending on the tumor size beyond 
100mm. Based on the relationship found in this study 
and in line with previous findings13, larger tumors may be 
selected to receive combination of  anthracycline and taxane 
or resectable ones could be considered for “toilet-like” 
mastectomy to debulk followed by adjuvant chemotherapy 
and radiotherapy. These suggestions require further studies.
Conclusion
Our study result supported the view that there is a relationship 
between breast cancer tumor size and response to NAC and 
there may be a need to stratify treatment beyond 100mm 
primary tumor size. Properly designed prospective clinical 
trials blocking confounding variables should be conducted 
to shed more light on this issue and to provide guidelines for 
decision making in the management of  large breast tumors 
in developing countries.
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